Perth, Mar 30, 2015 - (ABN Newswire) - PhytoTech Medical Limited (ASX:PYL) (the “Company”) advises that BBY Limited (“BBY”) initiated research on the Company on 19 March 2015 and has issued an updated research report dated 25 March 2015 in response to the Company’s proposed merger with MMJ Bioscience Inc. This research was not commissioned by the Company, however the Company does retain BBY on a corporate advisory basis.\
About: PhytoTech Medical Limited
PhytoTech Medical (ASX:PYL) is a medical cannabis company, which aims to commercialize Medical Grade Cannabis (MGC) and high potential cannabis based therapeutics products to the rapidly growing international market with regulated medical cannabis legislation. With research facilities located in Israel, a global leader in medical cannabis research, the Company is strategically positioned to become a key player in the global MGC market.
The Company is focused on the research, development and commercialization of products for administering MGC, and on new treatments utilizing MGC therapeutic components for various medical conditions. In addition, the Company aims to grow proprietary strains of MGC in California, Uruguay and other jurisdictions.
Help employers find you! Check out all the jobs and post your resume.
